Todd VanArsdale

机构：Pfizer (United States), Université Bourgogne Franche-Comté

发表论文 138 篇 · 总被引 5882 次 · h-index 32

代表论文

• Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity (2023 · Cell · 被引 182)
• CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety (2025 · Cancer Cell · 被引 65)
• An allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes (2024 · Nature Chemical Biology · 被引 19)
• Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors (2025 · Nature Communications · 被引 18)
• Abstract 5709: PF-07104091, a first-in-class CDK2-selective inhibitor for the treatment of HR+/HER2- breast cancer and CCNE1high ovarian cancer (2024 · Cancer Research · 被引 15)
• Expanding the ligandable proteome by paralog hopping with covalent probes (2024 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 7)